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Evidence suggests that the down-regulation of the signaling pathway involving brain-derived neurotrophic factor (BDNF), a molecular 
element known to regulate neuronal plasticity and survival, plays an important role in the pathogenesis of major depression. The resto-
ration of BDNF activity induced by antidepressant treatment has been implicated in the antidepressant therapeutic mechanism. Because 
there is variability among patients with major depressive disorder in terms of response to antidepressant treatment and since genetic fac-
tors may contribute to this inter-individual variability in antidepressant response, pharmacogenetic studies have tested the associations 
between genetic polymorphisms in candidate genes related to antidepressant therapeutic action. In human BDNF gene, there is a com-
mon functional polymorphism (Val66Met) in the pro-region of BDNF, which affects the intracellular trafficking of proBDNF. Because 
of the potentially important role of BDNF in the antidepressant mechanism, many pharmacogenetic studies have tested the association 
between this polymorphism and the antidepressant therapeutic response, but they have produced inconsistent results. A recent meta-
analysis of eight studies, which included data from 1,115 subjects, suggested that the Val/Met carriers have increased antidepressant re-
sponse in comparison to Val/Val homozygotes, particularly in the Asian population. The positive molecular heterosis effect (subjects 
heterozygous for a specific genetic polymorphism show a significantly greater effect) is compatible with animal studies showing that, al-
though BDNF exerts an antidepressant effect, too much BDNF may have a detrimental effect on mood. Several recommendations are 
proposed for future antidepressant pharmacogenetic studies of BDNF, including the consideration of multiple polymorphisms and a 
haplotype approach, gene-gene interaction, a single antidepressant regimen, controlling for age and gender interactions, and pharmaco-
genetic effects on specific depressive symptom-clusters.  Psychiatry Investig 2010;7:236-242
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BRAIN-DERIVED NEUROTROPHIC 
FACTOR, MAJOR DEPRESSION, AND 
ANTIDEPRESSANT DRUG ACTION
Major depressive disorder (MDD) has one of the highest 
lifetime incidence rates of all the psychiatric disorders.
1 Al-
though the causes of MDD are still unknown, causative factors 
can be artificially divided into biological and psychosocial fac-
tors, with probable interaction between the two.
2 For the biolog-
ical factors, earlier studies have demonstrated that the symp-
toms of depression can be improved by agents, which enhance 
the function of monoamine transmitters, particularly of norepi-
nephrine and serotonin. This finding led to the adoption of the 
monoamine hypothesis of depression and antidepressant ac-
tion, which has dominated both industrial and academic re-
search for approximately five decades. However, despite decades 
of MDD study, no conclusive abnormality has been identified 
in these two monoaminergic systems. Furthermore, current 
antidepressants are far from ideal owing to their slow onset of 
action and low rates of response.
3
In recent years, studies have begun to characterize the action 
of antidepressants and the pathogenesis of MDD beyond the 
neurotransmitter and receptor levels. An increase in the under-
standing of molecular mechanisms underlying antidepressant 
action has led to the suggestion that it is not the enhancement 
of monoaminergic signaling per se, but rather long-term neu-
roplastic changes which may underlie the therapeutic effect of 
antidepressants. The neurotrophic hypothesis of depression 
and antidepressant action was first proposed by Duman et al.
4 
in 1997. This hypothesis is based on the evidence that stress can 
decrease the expression of BDNF and lead to the atrophy of the 
Received: April 24, 2010    Accepted: September 7, 2010    
Available online: November 30, 2010
  Correspondence: Shih-Jen Tsai, MD
Department of Psychiatry, Taipei Veterans General Hospital, No. 201, Shih-Pai 
Road, Sec. 2, 11217, Taipei, Taiwan
Tel: +886-2-2875-7027, Fax: +886-2-2872-5643
E-mail: tsai610913@yahoo.com.tw
cc This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.SJ Tsai et al. 
   www.psychiatryinvestigation.org  237
same populations of stress-vulnerable hippocampal neurons, 
while electroconvulsive therapy (ECT) and antidepressants in-
crease BDNF expression and may reverse or block the atrophy 
and cell loss resulting from stress and depression.
5 In the past 
decade, this novel hypothesis has greatly changed the landscape 
for human and animal research on MDD.
BDNF is a small dimeric protein and is a member of the neu-
rotrophin family.
6 BDNF is widely expressed in the adult mam-
malian brain, the highest levels being found in the hippocampus, 
followed by those in the cerebral cortex.
7 Further, BDNF plays 
a key role in the regulation of neuronal survival, differentiation, 
growth, and apoptosis by binding to two types of receptors; name-
ly, the tyrosine kinase B (trkB) receptor and the p75 neurotroph-
in receptor (p75NTR).
8,9 Moreover, BDNF is involved in the reg-
ulation of synaptic synthesis and the release of neurotrans-
mitters.
10
The important role of BDNF in MDD and antidepressant 
drug action is supported by an increasing number of studies, 
mostly in animals. For example, long-term administration of 
antidepressants in animals upregulates the production of brain 
BDNF,
5 and infusion of BDNF itself into the midbrain has an 
antidepressant-like influence in animal models of depression.
11 
In a human postmortem study, Chen et al.
12 found that BDNF 
immunoreactivity was higher in the hippocampus of depressed 
subjects being treated with antidepressant medication at the 
time of death than in that of untreated controls. In a clinical 
study, Karege et al.
13 found that serum BDNF levels were signif-
icantly lower in MDD patients than in controls and that depres-
sion severity mainly accounted for a negative correlation be-
tween BDNF levels and depression scores. This finding has been 
replicated by Shimizu et al.
14 in their study of antidepressant-
naïve MDD patients, with these researchers further demon-
strating that reduced serum BDNF values returned to basal lev-
els after antidepressant treatment in drug-naïve patients.
The human BDNF gene has been mapped to chromosome 
11p13 and is composed of six 5’ exons, which are differentially 
spliced to a single 3’ terminal exon (exon 7) that encodes the en-
tire sequence of mature BDNF (GenBank accession no: AF411339). 
A common single nucleotide polymorphism (SNP) consisting 
of a missense change (G196A), which produces a non-con-
servative amino acid change (valine to methionine), has been 
identified in the coding exon of the BDNF gene at position 
66 (Val66Met, rs6265).
15 The replacement of 66Val by 66Met 
disrupts cellular processing, trafficking, and activity-dependent 
secretion of BDNF.
16 Our first studies on the genetic associa-
tion between the BDNF Val66Met polymorphism and MDD 
in outpatients
17 as well as inpatients
18 were in 2003. We found 
no significant differences in the genotype or allele frequency 
of the BDNF Val66Met polymorphism between the MDD 
and the control groups. However, in a subsequent genetic 
study, we found an association between BDNF Val66Met 
polymorphism and geriatric depression, chiefly in males.
19 
These findings are in line with a recent meta-analysis of 14 stud-
ies involving 2812 MDD cases and 10843 non-depressed con-
trols, which revealed that the BDNF Val66Met polymorphism 
is not significantly associated with MDD; however, male gen-
der and old age do have an impact on the association.
20
PHARMACOGENETIC STUDY OF BDNF 
AND THERAPEUTIC RESPONSE  
TO ANTIDEPRESSANTS
Antidepressant medication is the main treatment for MDD, 
but not all MDD patients benefit with up to 40% of MDD pa-
tients failing to respond to initial antidepressant treatment.
21 
Since genetic factors may play a substantial role in both the vari-
ation in response to treatment and incidence of adverse effects 
to medication, pharmacogenetic studies of antidepressant have 
attempted to identify genetic markers that predict treatment re-
sponse. Earlier antidepressant pharmacogenetic studies fo-
cused on genes related to monoaminergic systems. Among the 
candidate genetic variants tested, a serotonin transporter gene 
promoter polymorphism (5-HTTLPR) has been repeatedly as-
sociated with antidepressant treatment response.
22
Given that both clinical and preclinical studies suggest that 
BDNF may be involved in the therapeutic action of antidepres-
sants, BDNF appears to be a good candidate gene for the phar-
macogenetic study of antidepressants. In our 2003 study on 
110 MDD outpatients, we examined the association between 
the BDNF Val66Met polymorphism and response to 4-week 
antidepressant (fluoxetine) treatment.
17 A trend (p=0.086) to 
higher total HAM-D-score percentage change was noted for 
the Val/Met-heterozygote patients in comparison to those bear-
ing the homozygote (Val/Val or Met/Met). While similar 
findings have been reported in some of the subsequent stud-
ies of this polymorphism and the antidepressant response
23,24, 
other studies demonstrated a better response in subjects with 
the Met variant
25-27 or they found no association at all (Table 
1).
28,29 The inconsistencies in these findings might be due to 
the small sample sizes used in some of the studies. They could 
also have arisen as the result of differences in the antidepressants 
administered, in the methods for evaluating treatment outcome, 
in the length of treatment, and differences in the ethnic back-
ground and the MDD subtypes of the patients participating. 
In an earlier meta-analysis of four studies (490 subjects), a bet-
ter response was found in subjects with the Met allele.
30 How-
ever, this meta-analysis compared only the response between 
the Met carriers and the Val homozygotes. Recently, Zou et al.
31 
performed a meta-analysis which included eight studies with 
data from 1,115 subjects. They found that in the overall popu-238  Psychiatry Investig 2010;7:236-242
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lation the Val/Met genotype had a significantly stronger as-
sociation (p=0.02) with a higher response than did the Val/Val 
genotype. When stratified by ethnicity, similar results were found 
in Asians, but not in Caucasians. No association was found be-
tween the BDNF Val66Met polymorphism and the remission rate. 
The results of this meta-analysis suggest that Val66Met hetero-
zygous patients have a better response rate compared with Val/
Val homozygous patients, especially in the Asian population. The 
positive molecular heterosis effect (subjects heterozygous for 
a specific genetic polymorphism show a significantly greater ef-
fect) is compatible with the results of animal studies showing 
that, although BDNF exerts an antidepressant effect, too much 
BDNF may have a detrimental effect on mood.
32 Furthermore, 
although the increase in BDNF in the hippocampus due to an-
tidepressant treatment is associated with the therapeutic effect of 
the antidepressant, one animal study has shown that intra-ven-
tral tegmental area infusion of BDNF exerts a depression-like ef-
fect in the forced swim test.
33 Thus, an optimal rather than sim-
ply elevated BDNF level could be more important for the anti-
depression effect.
Several studies have investigated the therapeutic response to 
antidepressants associated with other BDNF genetic variants, 
apart from the BDNF Val66Met polymorphism. Recently, 
Gratacòs and colleagues
34 tested the association between the out-
come of antidepressant treatment in Spanish patients with 
mood disorders (226 MDD and 148 bipolar disorder cases) and 
genetic variants within the genomic region containing the BDNF 
gene. Of the eight BDNF polymorphisms tested, only the 
rs908867 SNP was associated with complete clinical remis-
sion. This polymorphism is located 229 bp upstream from the 
transcription starting site of exon 1 and is not considered to 
have an effect on the expression of the BDNF gene. Haplotype 
analysis revealed that the TAT haplotype (involving rs12273363, 
rs908867, and rs1491850 SNPs) is associated with a better ther-
apeutic response. However, the low base-rate of the TAT haplo-
type (0.069) may increase chance of false positives in the haplo-
type analysis. In the same study, the BDNF Val66Met polymor-
phism was tested, but no association was found with the thera-
peutic response to antidepressants. In a recent study, Licinio et 
al.
35 resequenced a genomic DNA region of 22 kilobases, which 
contained all BDNF exons and their flanking regions. They 
identified 83 novel BDNF polymorphisms. Association analy-
ses of 200 Mexican American MDD patients treated with de-
sipramine or fluoxetine revealed that 1 SNP (rs61888800) in 
the 5’ untranslated region was associated with antidepressant 
response after adjusting for age, sex, medication, and baseline 
depression score. In another study with 268 German MDD pa-
tients, among three BDNF polymorphisms tested (rs7103411, 
Val66Met, and rs7124442), the BDNF rs7124442 TT genotype 
was significantly related to worse treatment outcome over 6-week 
antidepressant treatment, particularly in patients with anxious 
depression.
26 This association seemed to originate solely from 
the female subgroup of patients. The BDNF rs7103411 and Val-
66Met polymorphisms were associated with treatment re-
sponse over six weeks only in clinical subtypes of depression, 
such as melancholic depression (Val/Val <Met/Met, p=0.001). 
The study also tested 10 markers in BDNF for association with 
the outcome of citalopram treatment in the Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D) sample 
(n=1,953), but no significant associations were found with 
any of the 10 BDNF markers.
In addition to MDD, antidepressants are also used in the treat-
ment of obsessive-compulsive disorder (OCD). Real et al.
36 test-
ed the association between the BDNF gene and antidepressant 
treatment outcome in OCD and found an association between 
therapeutic response and two of eight BDNF tag SNPs (rs908867 
Table 1. BDNF Val66Met polymorphism and response to antidepressant treatment
Authors
Number of
subjects
Type of antidepressants Results Ethnicity
Tsai et al.
17 110 Fluoxetine Heterozygous patients tended to have a better response than 
  the corresponding homozygous patients at 4 weeks
Asian
Choi et al.
25 83 Citalopram Met66 allele carriers were more likely to 
  have a better response at 8 weeks
Asian
Wilkie et al.
29 163 Various antidepressants No association with treatment outcome Caucasian
Yoshida et al.
23 134 Milnacipran, fluvoxamine Heterozygous patients tended to have a better response than 
  the corresponding homozygous patients at 6 weeks
Asian
Kang et al.
28 243 Mirtazapine No association with treatment outcome Asian
Zou et al.
24 295 Fluoxetine Heterozygous patients tended to have a better remission than 
  the corresponding homozygous patients at 6 weeks
Asian
Domschke et al.
26 268 Various antidepressants Met/Met patients had a better response than Val/Val patients 
  in the melancholic subgroup
Caucasian
Taylor et al.
27 229 Various antidepressants Met66 allele carriers were more likely to be remitted at 6 months CaucasianSJ Tsai et al. 
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and rs1491850).
In terms of non-pharmacological treatment in MDD, animal 
studies have shown that both ECT and repetitive transcranial 
magnetic stimulation (rTMS) have significant antidepressant 
action and both treatments affect brain BDNF levels.
5,37 A stu-
dy by Huuhka et al.
38 examined BDNF polymorphisms (Val-
66Met and C270T) and the response to ECT in 119 patients with 
MDD. No association was found between either Val66Met or 
C270T and the response to ECT in the total group of participants. 
In another study, the association between the BDNF Val66Met 
polymorphism and rTMS response was examined in a group of 
36 drug-resistant patients affected by mood disorders.
39 The re-
sponse to rTMS treatment was significantly greater in BDNF 
Val/Val homozygotes than in Met allele carriers (p=0.024).
PHARMACOGENETIC STUDY OF BDNF 
AND ANTIDEPRESSANT-RELATED 
ADVERSE EFFECTS
Although the activation of the BDNF-trkB pathway by anti-
depressants is related to the therapeutic mechanism of depres-
sion, too much BDNF activation may have adverse consequenc-
es. For example, animal studies found that transgenic over-
expression of BDNF has a facilitatory effect on anxiety-like 
behaviors
32 and learning and memory impairments.
40 A study 
by Zou et al.
24 demonstrated that insomnia and decreased sex-
ual desire, which are side effects of fluoxetine, may have been 
associated with the BDNF Val66Met polymorphism, and Met 
allele carriers showed a lower incidence of these adverse effects.
Antidepressant treatment can induce or increase suicidal 
tendencies in some MDD patients, particularly in young pa-
tients, and it has been suggested that the BDNF-trkB pathway 
may be involved in this antidepressant-emergent suicidality.
41 
This hypothesis was confirmed by a recent study, which inves-
tigated 123 polymorphisms in nine genes and found epistasis 
between BDNF and trkB genetic variants in vulnerability to 
suicidality after antidepressant treatment.
42
Antidepressant treatment for MDD patients can sometimes 
induce a manic affective shift, and elevated brain BDNF may be 
implicated in antidepressant-induced mania.
43 Furthermore, fam-
ily-based association studies have demonstrated that the BDNF 
Val66Met polymorphism is linked with bipolar disorders.
44,45 
Zai et al.
46 performed a case-control study to test for allelic frequen-
cy and genotype distribution differences across six BDNF poly-
morphisms between 27 patients with antidepressant-induced 
mania and 29 patients without antidepressant-induced ma-
nia. They did not observe any significant difference in either 
allelic or genotype frequencies between the two groups. How-
ever, with the small sample size used in this study, it may have 
been underpowered to detect a small, but real, association.
ANTIDEPRESSANT RESPONSE
IN Bdnf MUTANT MOUSE MODELS
The antidepressant response has been tested in genetically 
manipulated mice, and these studies may provide some infor-
mation for human BDNF-antidepressant pharmacogenetic re-
search. For example, Chen et al.
47 generated a variant Bdnf 
mouse [Bdnf (Met/Met)], which reproduces the phenotypic 
hallmarks observed in humans with the variant allele. The Bdnf 
(Met/Met) mice, which are similar to heterozygous Bdnf (+/-) 
knockout mice, exhibited increased anxiety-related behaviors, 
which were not normalized by the antidepressant, fluoxetine. 
However, the effect of fluoxetine in depression-related behaviors 
was not tested. More recently, Adachi et al.
48 used a viral-mediat-
ed gene transfer approach to assess the effect of BDNF in sub-
regions of the hippocampus on antidepressant responses. They 
found that the selective loss of BDNF in the dentate gyrus, but 
not in the CA1 region of the hippocampus, attenuated the actions 
of desipramine and citalopram in the forced swim test. Similar-
ly, another study demonstrated that imipramine decreased de-
spair behaviors (the tail suspension test) in wild-type, but not 
in heterozygous, Bdnf (+/-) knockout mice following unpre-
dictable chronic mild stress.
49 The above findings in Bdnf mu-
tant mouse models suggest that BDNF deficit dampens some 
aspects of antidepressant efficacy. However, it is unknown whe-
ther BDNF overactivity may affect antidepressant response. 
Studies to test antidepressant response in mutant mice with Bdnf 
overexpression are needed.
CONCLUSION AND FUTURE 
PERSPECTIVES
In summary, animal studies have shown that an increase in 
brain BDNF plays an important role in antidepressant action 
and that the antidepressant response is attenuated in mutant 
mice with BDNF deficit. However, the findings of the studies of 
the BDNF genetic effects on the therapeutic response of antide-
pressants are not consistent, although several studies on Asians 
suggested a molecular heterosis effect of the BDNF Val66Met 
polymorphism on the therapeutic response to antidepressants.
This article has reviewed the effects of BDNF polymorphisms 
on the therapeutic response of antidepressants. Given the di-
verse findings among the studies, several strategies for future 
antidepressant pharmacogenetic studies of BDNF are recom-
mended.
Firstly, some of the BDNF-antidepressant pharmacogenetic 
studies used a diverse range of antidepressants. Although BDNF 
plays an important role in the therapeutic effect of antidepres-
sants, it should be noted that different antidepressants may 
have different effects on brain BDNF expression. For example, 240  Psychiatry Investig 2010;7:236-242
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chronic amitriptyline (a tricyclic antidepressant) in rats in-
creased BDNF protein in the hippocampus.
50 However, anoth-
er study showed that chronic fluoxetine or desipramine admin-
istration in rats had no effect on BDNF protein in the hippocam-
pus.
51 These findings emphasise the importance of using a 
single antidepressant in BDNF pharmacogenetic studies.
52
Secondly, most of the BDNF-antidepressant pharmacoge-
netic studies investigated only the BDNF Val66Met polymor-
phism. Studies involving other BDNF SNPs may uncover impor-
tant information, which is currently being overlooked. Further-
more, the use of a haplotype constructed by several tag SNPs 
can improve genotyping efficiency by reducing the number of poly-
morphisms to be genotyped, and the haplotype itself may also 
tag other genetic variants, which affect gene function.
Thirdly, a single gene may play only a small part in the thera-
peutic response to antidepressants. Future studies should con-
sider genes in the BDNF signaling pathway, which may contrib-
ute or interact with BDNF in the response to antidepressant tr-
eatment. Recently, we found that one p75NTR missense poly-
morphism (S250L) was associated with the antidepressant res-
ponse,
53 and TrkB genetic variants may interact with the BDNF 
Val66Met polymorphism to contribute to the risk of geriatric 
depression.
54 We also found that SNPs in glycogen synthase ki-
nase-3beta (GSK3B), an important component in BDNF sig-
naling, were associated with the therapeutic effects of antide-
pressants.
55 In another study, we showed that genetic variants 
in plasminogen activator inhibitor type 1 gene (SERPINE1), which 
may be involved in the cleavage of proBDNF to mature BDNF 
in the brain,
56 are related to MDD susceptibility and also the acute 
therapeutic response to antidepressants.
57
Fourthly, it may be of interest to explore the interaction of 
BDNF and genes in serotonergic pathways in response to anti-
depressants. The serotonergic system and the BDNF pathway 
are two signaling systems, which play an important role in the 
pathogenesis and therapeutic mechanisms of MDD. A positron 
emission tomography study has shown that male carriers of the 
Val/Val genotype of the BDNF Val66Met polymorphism display 
higher serotonin transporter density in the brain.
58 Since both 
signaling systems have significant interactions with overlap-
ping functional targets, it might be expected that they would 
have synergistic genetic effects on response to antidepressant 
treatment or MDD. For example, a study by Kaufman et al.
59 
revealed a significant three-way interaction between the BDNF 
Val66Met genotype, the 5-HTTLPR genotype, and maltreat-
ment history in predicting MDD in children. Another study 
found a significant interaction between the 5-HTTLPR and 
BDNF Val66Met polymorphisms and the response to lithium 
prophylaxis in patients with bipolar disorders.
60 To our 
knowledge, there is no report of the interaction of these two 
polymorphisms with the antidepressant response in MDD pa-
tients.
Fifthly, the BDNF genetic effect on therapeutic responses to 
antidepressants may be on specific symptom clusters of MDD. 
In support of this notion, an animal study demonstrated that, 
while imipramine treatment decreased depression-like behav-
iors following unpredictable chronic mild stress in wild-type mice, 
but not in heterozygous Bdnf (+/-) knockout mice, the antide-
pressant did decrease anxiety-like behaviors in both genotypes.
49
Finally, the effect of BDNF on the brain may be affected by 
age because BDNF receptors change with age. For example, most 
BDNF genetic association studies in adult MDD showed no pos-
itive association with MDD susceptibility. However, two studies 
in geriatric depression patients found that the Met allele is a ge-
netic risk factor for MDD in aged subjects.
19,61 These findings are 
in line with those of an animal study, which showed that forebrain 
serotonin levels and fiber density in heterozygous Bdnf knock-
out mice are normal at an early age, but undergo premature age-
associated decrements.
62 In addition to age, gender may also in-
fluence BDNF genetic effects in the brain. For example, recent 
meta-analysis studies have revealed a sexually dimorphic effect 
of the BDNF Val66Met polymorphism on susceptibility to 
MDD
20 and to Alzheimer’s disease.
63 Interactions between 
age/gender and BDNF should therefore be considered in future 
antidepressant pharmacogenetic studies.
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